Ludwig Maximilian University of Munich

Eastdil Secured Appoints Juergen Fenk as Managing Director

Retrieved on: 
Tuesday, May 9, 2023

Eastdil Secured, LLC (“Eastdil Secured” or “the firm”), the global real estate investment bank, today announced that industry veteran Juergen Fenk will be joining the firm as Managing Director.

Key Points: 
  • Eastdil Secured, LLC (“Eastdil Secured” or “the firm”), the global real estate investment bank, today announced that industry veteran Juergen Fenk will be joining the firm as Managing Director.
  • At a pivotal moment for global real estate, Mr. Fenk brings more than 30 years of expertise in European investment banking and traditional real estate capital markets to Eastdil Secured.
  • “For more than 50 years, Eastdil Secured has provided clients with the expertise and insights they need to successfully adapt to and navigate through market cycles,” said Roy Hilton March, CEO of Eastdil Secured.
  • “Eastdil Secured has established itself as the premier and most trusted advisor in commercial real estate,” said Mr. Fenk.

Safety of Antiresorptive Drugs for Dental Implant Procedures

Retrieved on: 
Monday, May 1, 2023

LAWRENCE, Kan., May 1, 2023 /PRNewswire-PRWeb/ -- Journal of Oral Implantology – A possible complication known as Medication-related osteonecrosis of the jaw (MRONJ) concerns dentists and dental surgeons when patients take antiresorptive drugs (ARDs). ARDs induced side effects that can be critical for patients undergoing bone regeneration therapy before dental implant procedures. MRONJ can occur due to the disruption of blood flow to part of the jawbone. Ensuring patient well-being is highly important, so experts have widely debated the efficacy and safety of bone grafting and implant procedures for patients taking ARDs.

Key Points: 
  • LAWRENCE, Kan., May 1, 2023 /PRNewswire-PRWeb/ -- Journal of Oral Implantology – A possible complication known as Medication-related osteonecrosis of the jaw (MRONJ) concerns dentists and dental surgeons when patients take antiresorptive drugs (ARDs).
  • ARDs induced side effects that can be critical for patients undergoing bone regeneration therapy before dental implant procedures.
  • Ensuring patient well-being is highly important, so experts have widely debated the efficacy and safety of bone grafting and implant procedures for patients taking ARDs.
  • Full text of the article, "Clinical and Radiographic Outcomes of Dental Implants in Patients Treated with Antiresorptive Drugs: A Consecutive Case Series," Journal of Oral Implantology, Vol.

Immutep Appoints Dr. Florian Vogl as Chief Medical Officer

Retrieved on: 
Wednesday, April 26, 2023

SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces that Florian D. Vogl, M.D., Ph.D., MSc, has been appointed as Chief Medical Officer (CMO) with effect from 1 May 2023.

Key Points: 
  • SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces that Florian D. Vogl, M.D., Ph.D., MSc, has been appointed as Chief Medical Officer (CMO) with effect from 1 May 2023.
  • Dr. Vogl brings to Immutep over a decade of experience in the biopharmaceutical industry with extensive clinical development expertise in the field of oncology.
  • Dr. Vogl is a board-certified MD and had a career as a physician and clinical researcher in gynecology and oncology before moving to the biopharmaceutical industry.
  • Dr. Triebel will now foremost focus on his responsibilities as CSO and as a member of Immutep’s Board of Directors.

Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023

Retrieved on: 
Wednesday, February 22, 2023

PHILADELPHIA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced positive results from the global Phase 3 open-label extension (OLE) study (ATB200-07) to investigate the long-term efficacy and safety of AT-GAA in adult patients with late-onset Pompe disease, an inherited lysosomal disorder caused by an enzyme deficiency that leads to the accumulation of glycogen in cells. Study participants treated with AT-GAA for up to 104 weeks showed persistent and durable effects on six-minute walk distance (6MWD), stability in forced vital capacity (FVC), and continued reductions in biomarkers of muscle damage and disease substrate.

Key Points: 
  • These clinical results are being featured at the 19th Annual WORLDSymposium™ 2023 in a poster presentation and an oral platform presentation scheduled for Sunday, February 26, 2023, at 9:00 a.m.
  • The presentation will be given by Benedikt Schoser, MD, Department of Neurology, Ludwig-Maximilians-University of Munich and Principal Investigator in the PROPEL study.
  • Consistent with the Phase 1/2 study and the Phase 3 PROPEL study results, these first long-term results suggest that AT-GAA treatment for up to two years was associated with a durable effect.
  • No new safety signals were identified during the open label extension study.

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Retrieved on: 
Tuesday, January 17, 2023

Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB).
  • Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB.
  • Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D.
    “I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board,” said Dr. Walter Strapps, co-founder and CEO of Carver.
  • Dr. Sanjana holds a PhD in Brain and Cognitive Sciences from MIT, a BS in Symbolic Systems and a BA in English from Stanford University.

New Study Reports Broad Applicability of InGeneron’s Regenerative Cell Therapy System Across Patient Groups

Retrieved on: 
Saturday, January 7, 2023

The study, which characterized the composition of regenerative cells isolated from adipose tissue of 232 subjects using InGeneron’s Transpose® RT system, is the largest such study to date.

Key Points: 
  • The study, which characterized the composition of regenerative cells isolated from adipose tissue of 232 subjects using InGeneron’s Transpose® RT system, is the largest such study to date.
  • Utilizing high-fidelity technology to analyze the final cell product isolated from 232 subjects, the authors concluded the composition, concentration, and viability of regenerative cells were not significantly different across the subject groups that were studied.
  • Additionally, the authors analyzed 37 of the regenerative cell samples using flow cytometry to characterize specific cell types and still found no significant differences between subject groups; sex was not addressed in this sub-analysis.
  • The concentration of M2 macrophages isolated using InGeneron’s technology are, on average, three times higher than with any other system.

Sensei Biotherapeutics Provides Update on Strategic Priorities

Retrieved on: 
Thursday, December 8, 2022

BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- eSensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced a streamlining and realignment of resources to support its key indications and programs, including its lead antibody, SNS-101, a conditionally active antibody targeting the immune checkpoint VISTA, as well as its other TMAb™ (Tumor Microenvironment Activated biologics) platform programs.

Key Points: 
  • Sensei plans to relocate any ongoing work at its Boston research site to its Rockville, Maryland site.
  • “Our Board of Directors and management team remain focused on ensuring that Sensei is well positioned to execute on our near-term clinical and preclinical milestones.
  • Prior to joining Sensei in 2019, Dr. van der Horst worked at Zenith Epigenetics Ltd., Igenica Biotherapeutics Inc., OncoMed Pharmaceuticals, Tularik, Inc. (now Amgen) and U3 Pharma GmbH (now Daiichi-Sankyo).
  • Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients.

Asensus Surgical Announces Ludwig Maximilians University in Germany to Initiate Senhance Pediatric Surgery Program

Retrieved on: 
Tuesday, November 8, 2022

We are very excited that the LMU University Hospital will be utilizing a Senhance System as part of their pediatric surgery department.

Key Points: 
  • We are very excited that the LMU University Hospital will be utilizing a Senhance System as part of their pediatric surgery department.
  • This is a significant milestone for Asensus as this represents the first Senhance program devoted entirely to pediatric procedures, said Anthony Fernando, Asensus Surgical President and CEO.
  • We look forward to partnering with the pediatric team at LMU University Hospital to transform the way they deliver care to their pediatric patients.
  • The platform will be a great asset to our hospital, and we are very excited to launch our Senhance pediatric surgical program.

Sino-German "Generation Z" Uncover In-flight Meals with CEA Chefs

Retrieved on: 
Tuesday, November 1, 2022

On October 28, teachers and students from Chinese and German universities participated in the livestream activity hosted by China Eastern Airlines (CEA).

Key Points: 
  • On October 28, teachers and students from Chinese and German universities participated in the livestream activity hosted by China Eastern Airlines (CEA).
  • View the full release here: https://www.businesswire.com/news/home/20221031005581/en/
    Sino-German "Generation Z" Uncover In-flight Meals with CEA Chefs (Photo: Business Wire)
    The CEA German chef Ludwig Strobel led the students to make a virtual tour in China Eastern Air Catering Corporation, where he introduced to the students how in-flight meals are designed and hosted a mystery box Gourmet Challenge.
  • He also had had a heated discussion with students on topics such as "Explore Secrets of In-flight Meals" and "Sino-German Cuisine Culture.
  • CEAir On Air is an aviation cultural exchange activity for global universities organized by China Eastern Airlines since 2020.

Automation of Solid-Phase Aromatic Foldamer Synthesis, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, November 2, 2022

TORONTO, Nov. 2, 2022 /PRNewswire-PRWeb/ -- The synthesis of long helical oligoamide foldamers composed of more than 20 aromatic monomers of 8-amino-2-quinoline carboxylic acid can now be routinely achieved by using an in lab-developed solid-phase foldamer synthesis (SPFS) methodology that relies on acid chloride activation.

Key Points: 
  • In this free webinar, learn about aromatic oligoamide foldamer (AOF) chemistry and automated parallel solid-phase foldamer synthesis on a next-generation, multi-scale peptide synthesis platform and other applications.
  • That constitutes a critical milestone in the field of aromatic foldamer chemistry with many concrete applications such as the modulation of protein-protein interactions in competitive research programs.
  • Register for this webinar to learn more on aromatic oligoamide foldamer (AOF) chemistry, automated parallel solid-phase foldamer synthesis on the PurePep Chorus synthesizer a next-generation, multi-scale peptide synthesis platform and other applications.
  • For more information, or to register for this event, visit Automation of Solid-Phase Aromatic Foldamer Synthesis .